Machina Capital’s Neurocrine Biosciences NBIX Stock Holding History

Machina Capital’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$209K	Sell	1,241 -1,719	-58%	-$255K	0.03%	361
2026 Q1	$390K	Sell	2,960 -208	-7%	-$27.6K	0.08%	274
2025 Q4	$449K	Buy	+3,168	New	+$459K	0.09%	259
2024 Q4	–	Sell	-3,843	Closed	-$443K	–	339
2024 Q3	$443K	Buy	3,843 +828	+27%	+$114K	0.18%	191
2024 Q2	$415K	Sell	3,015 -254	-8%	-$34.8K	0.19%	193
2024 Q1	$451K	Sell	3,269 -900	-22%	-$123K	0.24%	162
2023 Q4	$549K	Buy	+4,169	New	+$480K	0.35%	112
2020 Q1	–	Sell	-4,102	Closed	-$441K	–	198
2019 Q4	$441K	Buy	4,102 +865	+27%	+$90.6K	0.18%	207
2019 Q3	$292K	Buy	+3,237	New	+$302K	0.13%	221

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Machina Capital's NBIX Position: Q2 2026 in Review

Machina Capital reduced its Neurocrine Biosciences (NBIX) stake by 58% in Q2 2026, selling an estimated $255K and leaving 1,241 shares worth $209K. The position accounts for 0.03% of the portfolio, ranked #361.

Machina Capital first reported a position in NBIX in Q3 2019 and has held it in 9 quarters since. The position peaked at $549K in Q4 2023. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Machina Capital held 1,241 shares of Neurocrine Biosciences worth $209K as of Q2 2026.
Machina Capital sold 1,719 Neurocrine Biosciences shares in Q2 2026, an estimated $255K.
Neurocrine Biosciences made up 0.03% of Machina Capital's portfolio in Q2 2026, its #361 holding.
Machina Capital first reported a position in Neurocrine Biosciences in Q3 2019 and has held it in 9 quarters since.
Machina Capital's Neurocrine Biosciences position peaked at $549K in Q4 2023.
781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Machina Capital's 13F filing for Q2 2026, filed 10 Aug 2026.